). In multivariate models, abacavir, P p .028 indinavir, efavirenz, and drug combinations that included both lamivudine and indinavir were the most effective treatments for achieving long-term suppression of VL (adjusted OR for each, 13.6; P value for each, !.01). Long-term suppression of VL is more likely in treatment-naive than in treatment-experienced patients, but there were several drugs-abacavir, efavirenz, indinavir, and drug combinations including lamivudine and indinavir-that appeared to be effective, whether they were part of a first or subsequent drug regimen.
achieved with therapy [3] , there has been increasing recognition that long-term suppression of VL is often unachievable, especially in patients who have previously received treatment [2] . Still, scrutiny of patients achieving this virological success may offer insights into factors that can benefit all HIV-infected patients [4] .
Observational studies of large numbers of outpatients in the community are necessary to assess therapies (e.g., in terms of criteria such as years of VL suppression) with efficacies that have been demonstrated in smaller, shorter, and controlled clinical studies. We analyzed a large subset of patients in the HIV Outpatient Study (HOPS) cohort who had had у2 VL determinations and for whom there were complete demographic, immunologic (CD4 + cell count), and drug treatment data. This analysis indicates that, regardless of patient demographic characteristics and antiretroviral treatment (ART) history, certain therapies are more successful than others for achieving long-term suppression of HIV load.
PATIENTS AND METHODS

HOPS cohort.
HOPS is an ongoing prospective observational study into which patients have been continuously recruited and followed up since 1992 [1, 5] . Study sites comprise 9 clinics (7 private, 2 public) in 8 US cities (Atlanta, GA; Chicago, IL; Denver, CO; Oakland, CA; Philadelphia, PA; Stony Brook, NY; Tampa, FL; and Washington, DC) where, as of this analysis, 16600 HIV-infected patients had made у1 visit and where ∼3000 HIV-infected patients per year currently receive care. Participating physicians have extensive experience treating HIV-infected patients; they usually see 1200 such patients per year.
Data from several general categories are abstracted on site shortly after each outpatient visit and are entered into an electronic database by trained data abstracters, are compiled centrally, and are reviewed and edited before being entered into the HOPS database. The categories of abstracted data include the following: demographic characteristics; HIV transmission risk factors; symptoms; diagnosed diseases (both definitive and presumptive); medications prescribed, including dose and treatment duration; and laboratory values, including CD4 + cell counts and plasma HIV-1 RNA loads. Because study physicians are the main source of primary HIV care for the patients, these physicians also note changes in the values of data abstracted from any of the above categories after each visit.
HOPS has yearly been reviewed and approved by the Centers for Disease Control and Prevention (Atlanta, GA) and by local institutional review boards since its inception; all participants provide written consent. The drugs examined were approved by the US Food and Drug Administration as of the middle of 2001, although many of the newer drugs thought to be clinically effective, such as lopinavir/ritonavir, could not be assessed in this study, which required 12 years of observation of both case and control patients.
Patients. The aim of our study was to compare data for persons who achieved long-term suppression (i.e., undetectable levels for у2 years) of VL (case patients) with data for persons who did not achieve or maintain suppression of VL (control patients). We considered long-term suppression to have occurred in any individual who, for у24 consecutive months from January 1993 through December 2001, had no intervening detectable VL, as revealed by results of у2 sequentially performed tests that were below the lower limits of detection (i.e., !400 copies/mL or !50 copies/mL). RT-PCR (successive versions of Amplicor HIV-1 Monitor; Roche Diagnostics) was used, or, in ∼10% of cases, the b-DNA assay (Chiron). We included the conservative criterion that a single detectable VL, even if small (i.e., a "blip" [6] ), disqualified an individual from inclusion in the group of case patients; disqualified individuals were included in the control group.
Control patients were those who had у2 VL determinations within у24 months, any of which showed detectable VL, including those with blips. The time of observation of case patients started when they first had an undetectable VL during enrollment in HOPS, and the treatment of interest was the ART they were receiving at that time. The time of observation of control patients started when their VL was first detected during enrollment in HOPS, and the treatment of interest was the ART they were receiving at that time.
Case and control patients were compared on the basis of demographic information, HIV-transmission risk, education level, source of health care financing (private vs. public), CD4 + cell count (baseline, nadir, and most recent), history of ART treatment (naive vs. previously treated), and single-dose or combination ART received.
Because persons who had detectable VLs tended to be extensively pretreated (i.e., they had received most antiretroviral drugs at one time or another), we compared ART received by case and control patients when their VL was first undetectable and detected, respectively. We also performed analyses comparing the individual drugs and the drug combinations administered to case and control patients after January 1993.
Some of the patients from the HOPS cohort in this analysis also filled out a confidential survey in 1999 regarding their adherence to their ART regimen [Knoll et al., unpublished data]. In a subanalysis of this sample of patients, we compared adherence between study participants receiving specific study drugs and participants not receiving those drugs on the basis of confidential reports of having skipped at least 1 dose in the 3 days before the survey was administered.
Statistical analysis. Data analysis was performed using SAS, version 8.0 (SAS Institute). We first performed univariate analyses for factors associated with long-term suppression of VL, and we calculated ORs and 95% CIs using the CochranMantel-Haenszel test, the Wald P 2 test, and Fisher's exact test. On the basis of results of the univariate analyses, we constructed multivariate (logistic regression) models from covariates known to be significantly associated with long-term VL suppression in the univariate model. This was done in a stepwise manner in the order of covariate significance. Because more sensitive tests for measuring plasma HIV RNA loads are now used, we also performed subanalyses using multivariate models of data for persons who had their final 2 undetectable VLs determined by the more recent and sensitive VL tests (lower limit of detection, 50 copies/mL).
RESULTS
There were complete demographic, virological, immunologic, and treatment data for 1235 patients, 286 (23.1%) of whom had repeated undetectable VLs (without intervening detectable VLs) that were у2 years apart. There were 17,695 VL assays performed on samples obtained from these patients; 8374 (47.3%) were tests with a lower limit of detection of 400 HIV RNA copies/mL. The remaining assays had a lower limit of detection of 50 HIV RNA copies/mL. During a mean observation period of 3.1 years (range, 2.0-5.2 years), 3103 VL tests were performed on samples obtained from the 286 case patients in this analysis, of which 948 tests (30.6%) had a lower limit of detection of 400 copies/mL (mean number of VL assays per person-year of observation, 3.5 [2.4 for assays with a cutoff of !50 copies/mL]). During a mean observation period of 4.0 years (range, 2.0-5.9 years), 14,592 VL tests were performed on samples obtained from the 949 control patients, of which 7426 tests (50.9%) had a lower limit of detection of 400 copies/ mL (mean number of VL assays per person-year of observation, 4.0 [1.9 for assays with a cutoff of !50 copies/mL]).
Compared with the 949 HIV-infected control patients in the HOPS cohort, the case patients were more likely to be male, white, gay, college graduates, and privately (as opposed to publicly) insured, and, at baseline, to have had lower VLs and higher CD4
+ cell counts (table 1) . They were more likely to be treatment-naive than to have received any ART (table 1) .
The mean number of treatment regimens prescribed during the periods of observation was 2.0 for case patients and 5.7 for control patients ( , by Student's t test). For 249 case P ! .001 patients, information on why they changed regimens showed that 94 (37.8%) changed because of drug toxicity or intolerance, 53 (21.2%) changed because 1 drug had been added to the previous regimen, 31 (12.5%) changed because of changing standards of care (such as receipt of HAART), and 28 (11.2%) changed for other or unspecified reason(s). The case patients received antiretrovirals for the following mean durations: abacavir, 1. Certain antiretroviral drugs, such as those used in combination drug therapies at the start of the case patient observation period, were found to be highly effective in unadjusted analyses, analyses stratified for whether patients were drug-naive or not, or multivariate analysis for many covariates (table 2). In addition to those drugs found to be most effective in unadjusted and adjusted models (i.e., abacavir, indinavir, and efavirenz; table 2), the following drugs were also found to have statistically significant efficacy in unadjusted analysis: lamivudine (unad- ). However, in the subanalysis of 133 P p .022 (10.8%) of these persons who were randomly selected and surveyed for their adherence to the therapy regimen [Knoll et al., unpublished data] regardless of their sex, race, or risk group, patients who received lamivudine, efavirenz, or indinavir therapy (abacavir is not included because too few people had received it and had filled out the 1999 survey) were no more or less adherent than persons receiving other drugs (P value for each therapy, у.09).
Comparative analyses of individual drugs or common drug combinations administered after the start of periods of observation were not helpful, because the control patients had a mean of 5.7 drug changes during their periods of observation and, therefore, had received most drugs. Thus, in such analyses, some drugs were significantly negatively correlated with longterm suppression of VL, and no drugs were significantly positively correlated with VL suppression (data not shown).
DISCUSSION
These data indicate that the following patients are more likely than others to achieve and maintain undetectable HIV loads for a long time: white gay men who are better educated, are privately insured, and are starting ART for the first time, and, especially, who have higher CD4
+ cell counts and lower initial VLs [2] . More interesting, multivariate analysis controlling for these factors showed that, regardless of the demographic, virological, and immunologic characteristics of patients, certain antiretroviral agents and combination therapies were highly efficacious for long-term suppression of VL. The most effective ARTs in our study were abacavir, indinavir, or efavirenz (all of which were administered with other drugs) or 2 common com- binations that consisted of indinavir and lamivudine combined with either zidovudine or stavudine. These drugs, especially efavirenz [7] , have been highly effective for suppressing HIV loads in many patients for a relatively short period (!1 year). Reports at the July 2002 International Conference on AIDS (Barcelona, Spain) from other longer-term studies of ambulatory patients are beginning to demonstrate just such superiority of abacavir, lamivudine, and efavirenz [8] [9] [10] [11] [12] .
White gay men in our analysis were more likely to have received these drugs, and it is possible that they were more adherent to their regimens. However, our study of adherence in randomly selected HOPS patients in 1999 did not find this to be the case [Knoll et al., unpublished data], and, in any case, subanalysis of 133 patients who were receiving these effective drugs did not show them to be more or less adherent than persons for whom other drug regimens were prescribed.
VL suppression may not be the best way of evaluating ART success. Maintaining constant or improving CD4 + cell counts [13] , gaining weight, or returning to work (or other measures of functional status) may all represent alternate indices of ART success. Nonetheless, given that VL determinations remain useful and objective indices of ART efficacy [14] , finding that particular drugs or drug combinations are more successful than others for suppressing viremia may be helpful in designing ART regimens.
Observational cohorts such as HOPS are valuable for evaluating the long-term outcomes of ART in HIV-infected patients but necessarily suffer from several drawbacks [15] . For example, the superiority of efavirenz in this analysis could have resulted from clinician experience with other earlier formulations of drugs in the same class (i.e., nevirapine). Also, use of dynamic cohorts does not allow systematic monitoring of virological and immunologic parameters at fixed time intervals. Patients with long-term suppression of VL (for 12 years) might have detectable VLs from time to time. Still, the information available at this time does not suggest that transient low-level HIV viremia is, in fact, associated with clearly worse outcomes than those associated with long-term suppression [2, 6, 16] , even though, in this analysis, persons with such low-level viremia were conservatively assigned to the control group. The control patients underwent more VL testing than did the case patients (mean, 4.0 vs. 3.5 tests per year), which was probably associated with their many changes in therapy, and so might have had more opportunity for detectable VLs to be noted. However, they underwent fewer tests that had the more stringent threshold of undetectability (!50 HIV RNA copies/ mL) than did the case patients (mean, 1.9 vs. 2.4 tests per year). Therapy adherence is nearly impossible to measure consistently, reliably, and reproducibly in a long-term dynamic cohort such as HOPS, and, although we do report adherence data for some persons, we still think this report should be considered as an intention-to-treat analysis. However, it would be unusual for any of these unmeasured biases to nullify adjusted ORs that were usually 13.6 ; the strength of these statistical associations is unlikely to be due to either chance or bias.
In summary, about one-fourth of well-characterized patients in the HOPS cohort had long-term suppression (for 12 years) of plasma HIV RNA load to levels undetectable by currently available assays. Although this analysis, by definition, could not evaluate the population-effectiveness of ARTs introduced during the previous 2 years, specific drugs-namely, abacavir, indinavir, efavirenz, and nucleoside reverse-transcriptase inhibitors in combination with indinavir and lamivudine-were all highly effective. Clinicians may consider these data in designing ART regimens for their HIV-infected patients. 
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